MicroPort Announced 12-Month Follow-Up Result of FOCUS

The 5th Oriental Congress of Cardiology (OCC 2011) was held at Shanghai International Convention Center from May 26 to May 29. During the congress, MicroPort organized a satellite meeting on the application of Firebird2 drug-eluting stents in the treatment of small vessel disease and tortuous lesions, and simultaneously announced the final result of its clinical-registered study FOCUS.
 
According to the 12-month follow-up of FOCUS, the success rate was high, with 99.81% lesion achievement ratio and 99.72% case achievement ratio. It was also shown that the 12-month cumulative cardiac death rate was 0.84%, the incidence of TVR, MACE and Late Thrombosis were 0.90%, 3.43% and 0.75%, respectively. The follow-up data further validated and proved the clinical safety and efficacy of Firebird2 drug-eluting stents.